Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 MINI Act ORPHAN Act Mental Health Appropriations Language FY26
2025 · 1st Quarter (Jan 1 - Mar 31)
BRISTOL-MYERS SQUIBB COMPANY
Filed by BRISTOL-MYERS SQUIBB COMPANY.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2025
- Income
- Not reported
- Expenses
- $870,000.00
- Registrant
- BRISTOL-MYERS SQUIBB COMPANY
- Filing UUID
- ac27ea6b-f56a-4779-8bd3-03f51fa7fa2c
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act
Literal federal measure citations: H.R.7635
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation
Intellectual Property Reform concerning bio-pharmaceutical industry
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act
Literal federal measure citations: H.R.830, S.127, H.R.3283, S.1339, H.R.5378, S.2973, H.R.8412
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.